Tenax Therapeutics: Millennium-linked holders report ~2% stakes

Tenax Therapeutics, Inc. Schedule 13G/A amendment reports beneficial ownership stakes by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Rhea-AI Filing Summary

Tenax Therapeutics, Inc. Schedule 13G/A amendment reports beneficial ownership stakes by Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. The filing lists 448,475 shares (1.7%) attributed to Integrated Core Strategies and 533,889 shares (2.1%) attributed to each of Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

The filing states these shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and includes a Joint Filing Agreement dated May 7, 2026.

Insights

Institutional Ownership Analyst

Concentrated institutional holdings around 2% reported by Millennium-affiliated entities.

The amendment discloses 533,889 shares (2.1%) for Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, and 448,475 shares (1.7%) for Integrated Core Strategies (US) LLC. These counts are presented as shared voting and dispositive power.

Ownership is described as held by entities subject to voting control and investment discretion by Millennium Management LLC; the filing includes a Joint Filing Agreement dated May 7, 2026. Filings of this type are routine disclosures of passive or group holdings under Schedule 13G/A.

Compliance & Governance Specialist

Group filing and attribution clarifies voting/dispositive relationships among filers.

The cover responses show shared voting and shared dispositive power for the disclosed share counts, and Item 4 explains the holdings are held by entities subject to Millennium-affiliated control. The Joint Filing Agreement is attached as Exhibit I.

These details document group coordination and attribution; their practical impact depends on trading/activity by the underlying entities and any future amendments.

Key Figures

Integrated Core Strategies holdings: 448,475 shares Millennium Management holdings: 533,889 shares Millennium Group Management holdings: 533,889 shares +2 more

5 metrics

Integrated Core Strategies holdings 448,475 shares shared voting/dispositive power; <date>as reported on cover</date>

Millennium Management holdings 533,889 shares shared voting/dispositive power; <date>as reported on cover</date>

Millennium Group Management holdings 533,889 shares shared voting/dispositive power; <date>as reported on cover</date>

Israel A. Englander holdings 533,889 shares shared voting/dispositive power; <date>as reported on cover</date>

Joint Filing Agreement date May 7, 2026 Exhibit I attached to amendment

Key Terms

Schedule 13G/A, Shared Dispositive Power, Joint Filing Agreement, Beneficially owned

4 terms

Schedule 13G/A regulatory

"Amendment No. 2 Tenax Therapeutics, Inc. Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Shared Dispositive Power financial

"Shared Dispositive Power 448,475.00"

Joint Filing Agreement regulatory

"Exhibit I: Joint Filing Agreement, dated as of May 7, 2026"

Beneficially owned financial

"Amount beneficially owned: See response to Item 9 on each cover page"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Tenax Therapeutics (TENX) Schedule 13G/A amendment disclose?

It discloses beneficial ownership stakes by Millennium-related entities. The filing lists 533,889 shares (2.1%) for Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, and 448,475 shares (1.7%) for Integrated Core Strategies (US) LLC.

Who are the filers on the TENX Schedule 13G/A amendment?

Filers are Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander, with addresses c/o Millennium Management LLC at 399 Park Avenue, New York.

What voting and dispositive powers are reported in the TENX filing?

The filing reports shared voting power and shared dispositive power for the disclosed share counts: 448,475 and 533,889 respectively, with sole powers reported as 0 on the cover responses.

Is there an agreement among the filers in the TENX Schedule 13G/A?

Yes. The amendment attaches a Joint Filing Agreement dated May 7, 2026 as Exhibit I among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

Does the TENX filing admit beneficial ownership by Millennium entities?

No. Item 4 states the described relationships "should not be construed" as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander; the filing explains control and discretion relationships instead.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 06:19 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Tenax Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

88032L605

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Integrated Core Strategies (US) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 448,475.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 448,475.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

448,475.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 533,889.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 533,889.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

533,889.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 533,889.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 533,889.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

533,889.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 88032L605

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 533,889.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 533,889.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

533,889.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tenax Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina 27517
Item 2.
(a)	Name of person filing: Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 88032L605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Integrated Core Strategies (US) LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/07/2026

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/07/2026

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	05/07/2026

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	05/07/2026

Comments accompanying signature: ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of May 7, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.